Avacta Group PLC Director/PDMR Shareholding (6008D)
July 08 2016 - 2:00AM
UK Regulatory
TIDMAVCT
RNS Number : 6008D
Avacta Group PLC
08 July 2016
08 July 2016
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Director's Dealing
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics and research reagents, announces that application
has been made to AIM for the admission of 3,393 new ordinary shares
of 10p each (the "New Ordinary Shares").
The New Ordinary Shares have been allotted pursuant to the
purchase by Michael Albin, Non-Executive Director of the Company,
of new ordinary shares in accordance with the terms set out in the
Company's announcement of 23 February 2016.
As set out in the Company's announcement of 23 February 2016, on
22 February 2016 Mr Albin entered into a binding commitment to
purchase GBP3,125 of new Avacta shares per quarter and the New
Ordinary Shares represent his investment for the period of 1 April
2016 to 30 June 2016. Mr Albin purchased the New Ordinary Shares on
7 July 2016 at a price of 92.1 pence per share.
Following admission of the 3,393 New Ordinary Shares to trading
on AIM, the total number of ordinary shares with voting rights in
issue will be 68,379,282 and this figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure and Transparency Rules.
Admission of the New Ordinary Shares ("Admission"), which will
rank pari passu in all respects with the Company's existing shares
in issue, is expected to occur on 13 July 2016. Following
Admission, Mr Albin will be interested in a total of 4,292 ordinary
shares of 10p each in the Company, representing less than 0.1% of
the Company's issued share capital.
Enquiries:
Avacta Group plc Tel: +44 (0)
Alastair Smith, Chief Executive 844 414 0452
Officer www.avacta.com
Tony Gardiner, Chief Financial
Officer
Numis Securities Limited Tel: +44 (0)
Michael Meade / Freddie Barnfield 207 260 1000
- Nominated Adviser www.numiscorp.com
James Black - Corporate Broking
WG Partners Tel: +44 (0)
David Wilson 203 705 9318
Nigel Barnes Tel: +44 (0)
Claes Spang 203 705 9217
www.wgpartners.co.uk
Media Enquiries Tel: +44 (0)
FTI Consulting 203 727 1000
Simon Conway / Natalie Garland-Collins avacta@fticonsulting.com
Notes to Editors
Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Antibodies dominate markets worth in excess of $50bn despite
their shortcomings. Affimer technology has been designed to address
many of these negative performance issues, principally; the time
taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. Affimer technology is based on a small protein that
can be quickly generated to bind with high specificity and affinity
to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an
in-house focus on immuno-oncology and bleeding disorders as well as
partnered development programmes. Avacta is commercialising
non-therapeutic Affimer reagents through licensing to developers of
life sciences research tools and diagnostics.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHAKODNPBKDAOK
(END) Dow Jones Newswires
July 08, 2016 02:00 ET (06:00 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024